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Thrombotic diseases, in which a deregulated clot formation occurs, remain a major cause of death in industrialised countries. Anticoagulants are part of the strategies to address these disorders. However current available drugs are still associated with risk of severe bleeding complications. Novel and safe antithrombotics are thus required. 
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Based on these considerations, the purpose of our project is to develop novel selective FXIIa inhibitors to detail the exact role of this enzyme in thrombotic diseases. These compounds could also be a good starting point for the development of new antithrombotic drugs. 

The 3-carboxamide coumarins were previously described as nonpetidic and selective inhibitors of FXIIa HYPERLINK \l "_ENREF_3" \o "Robert, 2008 #24"  ADDIN EN.CITE <EndNote><Cite><Author>Robert</Author><Year>2008</Year><RecNum>24</RecNum><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>24</rec-number><foreign-keys><key app="EN" db-id="xtawz9pwvez024ep2ecpx9092pf22tete5ar">24</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Robert, S.</author><author>Bertolla, C.</author><author>Masereel, B.</author><author>Dogne, J. M.</author><author>Pochet, L.</author></authors></contributors><auth-address>Department of Pharmacy, Drug Design and Discovery Center, FUNDP, University of Namur, Namur, Belgium.</auth-address><titles><title>Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors</title><secondary-title>J Med Chem</secondary-title></titles><pages>3077-80</pages><volume>51</volume><number>11</number><edition>2008/05/08</edition><keywords><keyword>Amides/ chemical synthesis/chemistry</keyword><keyword>Anticoagulants/ chemical synthesis/chemistry</keyword><keyword>Coumarins/ chemical synthesis/chemistry</keyword><keyword>Factor XIIa/ antagonists &amp; inhibitors/chemistry</keyword><keyword>Structure-Activity Relationship</keyword></keywords><dates><year>2008</year><pub-dates><date>Jun 12</date></pub-dates></dates><isbn>0022-2623 (Print)&#xD;0022-2623 (Linking)</isbn><accession-num>18459730</accession-num><urls></urls><electronic-resource-num>10.1021/jm8002697</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>3. However, their low solubility and poor pharmacokinetics resulted in a lack of activity in in vivo models of thrombosis HYPERLINK \l "_ENREF_4" \o "Kraft, 2010 #33"  ADDIN EN.CITE <EndNote><Cite><Author>Kraft</Author><Year>2010</Year><RecNum>33</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>33</rec-number><foreign-keys><key app="EN" db-id="xtawz9pwvez024ep2ecpx9092pf22tete5ar">33</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kraft, P.</author><author>Schwarz, T.</author><author>Pochet, L.</author><author>Stoll, G.</author><author>Kleinschnitz, C.</author></authors></contributors><auth-address>Department of Neurology, Josef-Schneider-Str, 11, University Clinic of Wuerzburg, Germany.</auth-address><titles><title>COU254, a specific 3-carboxamide-coumarin inhibitor of coagulation factor XII, does not protect mice from acute ischemic stroke</title><secondary-title>Exp Transl Stroke Med</secondary-title><alt-title>Experimental &amp; translational stroke medicine</alt-title></titles><periodical><full-title>Exp Transl Stroke Med</full-title><abbr-1>Experimental &amp; translational stroke medicine</abbr-1></periodical><alt-periodical><full-title>Exp Transl Stroke Med</full-title><abbr-1>Experimental &amp; translational stroke medicine</abbr-1></alt-periodical><pages>5</pages><volume>2</volume><number>1</number><edition>2010/03/20</edition><dates><year>2010</year></dates><isbn>2040-7378 (Electronic)&#xD;2040-7378 (Linking)</isbn><accession-num>20298537</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/20298537</url></related-urls></urls><custom2>2831840</custom2><electronic-resource-num>10.1186/2040-7378-2-5</electronic-resource-num><language>eng</language></record></Cite></EndNote>4. Therefore, we aim to improve these characteristics while keeping the selectivity and potency towards FXIIa.
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